Hints and tips:
Related Special Reports
...A number of celebrity endorsements and the success of Novo Nordisk and Eli Lilly’s treatments in helping users lose weight have made the drugs hugely popular, sparking supply shortages....
...BeiGene said it was “finalising a second source of API outside of China” as part of a process that began in 2019. Eli Lilly and Vertex declined to comment on the talks....
...But the companies do not have a history of protein manufacturing used by Novo Nordisk and its US rival Eli Lilly to make their diabetes and weight-loss products....
...Academics are boycotting a leading gender studies journal owned by New York-listed publisher Wiley after its editors and policies were changed in what they characterise as an “anti-woke” drive against radical...
...Eli Lilly’s weight-loss drug tirzepatide significantly reduced sleep apnoea problems in a late-stage clinical trial, the pharmaceutical group said on Wednesday, adding to evidence that could encourage more...
...A decision on Eli Lilly’s donanemab drug from the US Food and Drug Administration was originally due by the end of the first quarter, but the medicine will now be subject to a further review by an advisory...
...The push into prescriptions and drug delivery is unusual for a pharmaceutical manufacturer, pitting Eli Lilly against US pharmacy chains such as CVS and Walgreens. Read more here...
...“We’re pleased to work with Lilly to reimagine a pharmacy experience that can support better care outcomes.”...
...A decision from the US Food and Drug Administration on Eli Lilly’s donanemab drug was originally due by the end of the first quarter but the breakthrough medicine will now be subject to a further review...
...“It’s not like Lilly and Novo will never be able to fulfil demand,” he said. “It’s just that it can take three to five years to get a facility standing and running.”...
...Demand for a new class of diabetes and obesity drugs will boost US drugmaker Eli Lilly’s sales by 20 per cent in 2024, pushing its revenues above $40bn, the company said on Tuesday....
...Dear reader, It isn’t often that a company pays good money to criticise customers for buying its product. But that is what Eli Lilly did this week....
...Lilly’s valuation may seem impossibly high but don’t expect a correction to come any time soon....
...The retail giant struck a deal earlier this month to dispense medication on behalf of Zepbound maker Eli Lilly’s direct-to-consumer service LillyDirect....
...In the race to develop a small molecule pill, Eli Lilly’s phase 3 orforglipron was “a bit of a frontrunner”, Novo Nordisk’s Lange acknowledged, but he said it was not as effective as injectables....
...After the MHRA announced authorisation of Eli Lilly’s “KwikPen” on Thursday, a format that provides four doses in one device, the company has said it will now be able to supply the drug to England, Scotland...
...Surging demand for a new class of diabetes and weight-loss drugs has caused a huge jump in revenues at Novo Nordisk and Lilly, creating a market that could be worth about $100bn by the end of the decade,...
...Lilly expects the new jab to be available before the end of the year....
...Lilly’s drug....
...Eli Lilly’s donanemab slowed cognitive decline by 35 per cent, albeit with a higher incidence of brain swelling, known as amyloid-related imaging abnormalities (Aria)....
...The world’s largest pharmaceutical company by market capitalisation now expects earnings per share to be between $6.50 and $6.70, compared with a previous outlook of between $9.70 and $9.90....
...Lilly expects to sell the new jab at a list price of nearly $1,060, but said this would be 20 per cent lower than Wegovy....
...Novo Nordisk and Eli Lilly have broken records for deals for weight-loss drugs this year, buying a series of biotechs in a bid to ensure that their dominance in the fast-growing market lasts for years....
...Eli Lilly’s $12.50 a share cash offer for Point represents a 50 per cent premium to the stock’s undisturbed three month average....
International Edition